Welcome to our dedicated page for argenx SE American Depositary Shares news (Ticker: $ARGX), a resource for investors and traders seeking the latest updates and insights on argenx SE American Depositary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect argenx SE American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of argenx SE American Depositary Shares's position in the market.
argenx SE reported $398 million in first quarter global net product sales, with FDA review ongoing for CIDP sBLA and a PDUFA target action date of June 21, 2024. The company is on track to submit a filing for a pre-filled syringe in the second quarter of 2024. VYVGART SC played a significant role in driving growth, expanding prescriber base and reaching new patients. Multiple regulatory decisions are expected in 2024 for VYVGART and VYVGART SC, with plans for further expansion and development of the pipeline.
On May 7, 2024, argenx SE announced the results of its Annual General Meeting of shareholders. The meeting approved the annual report and accounts for the financial year ending December 31, 2023. Dr. Brian L. Kotzin was appointed as a non-executive director, while Peter Verhaeghe and Dr. Pamela Klein were re-appointed. The Board of Directors was authorized to issue shares and amend the articles of association. Deloitte Accountants B.V. and Ernst & Young Accountants LLP were appointed as auditors for the 2024 and 2025 financial years, respectively.
argenx, a global immunology company, will participate in a fireside chat at the BofA Securities 2024 Health Care Conference. The event will take place on May 14, 2024, in Las Vegas, NV, and will be live-streamed on the argenx website. This participation highlights the company's commitment to improving the lives of individuals with severe autoimmune diseases.
argenx, a global immunology company, will report its first quarter 2024 financial results and provide a business update on May 9, 2024. The company will host a conference call and webcast to discuss the results and future plans. Investors can access the webcast on the company's website. Dial-in numbers are provided for different countries.